ID   WIL2:RD1694
AC   CVCL_Y425
DR   Wikidata; Q54994069
RX   PubMed=7537518;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_5847; ICI D1694 (Tomudex; ZD1694).
CC   Sequence variation: Mutation; HGNC; HGNC:11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6544 ! WIL2
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 07-11-14; Last updated: 10-04-25; Version: 13
//
RX   PubMed=7537518; DOI=10.1038/bjc.1995.178; PMCID=PMC2033796;
RA   Jackman A.L., Kelland L.R., Kimbell R., Brown M., Gibson W.,
RA   Aherne G.W., Hardcastle A., Boyle F.T.;
RT   "Mechanisms of acquired resistance to the quinazoline thymidylate
RT   synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell
RT   lines.";
RL   Br. J. Cancer 71:914-924(1995).
//